Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 24, 2015 5:23 PM ET


Company Overview of ADC Therapeutics SA

Company Overview

ADC Therapeutics SA develops antibody drug conjugates (ADCs) and non-antibody drug conjugate products. The company is based in Lausanne, Switzerland. ADC Therapeutics SA operates as a subsidiary of Celtic Therapeutics Holdings L.P.



Key Executives for ADC Therapeutics SA

Chief Executive Officer
Co-Founder, Chairman and Managing General Partner of Auven Therapeutics
Age: 67
Director of Finance
Senior Vice President of Research & Development
Chief Medical Officer and Head of Oncology Clinical Development
Compensation as of Fiscal Year 2015.

ADC Therapeutics SA Key Developments

ADC Therapeutics Sarl Presents at BIO-Europe 2015, Nov-02-2015

ADC Therapeutics Sarl Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

ADC Therapeutics Announces Board Changes

ADC Therapeutics announced that Dr. Hans-Peter Wild and Jacques Theurillat have been appointed to its board of directors as non-executive directors. Dr. Wild is the owner and Chairman of the Wild Group and has built multiple global businesses, including Wild Flavours GmbH. As an independent non executive director, Mr. Theurillat brings to the Board extensive experience in strategy development, finance and commercial operations. He has been CEO of Ares Life Sciences AG and previously served as CEO and Chairman of Albea Pharmaceuticals AG. He also had an extensive career at Serono, which spanned roles such as Chief Financial Officer, Deputy Chief Executive Officer and Senior Executive Vice President, Strategic Corporate Development.

ADC Therapeutics Sarl Announces Executive Changes

ADC Therapeutics Sarl announced the appointment of Dr. Chris Martin as its Chief Executive Officer. Dr. Martin was co-founder of Spirogen Ltd. and its Chief Executive Officer. Dr. Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Dr. Martin will continue to advise Medimmune as a consultant. Dr. Martin replaces Michael Forer who has served as CEO of the company since its formation. Mr. Forer is a Partner in the private equity firm Auven Therapeutics and was the lead investor on behalf of Auven for its majority investments in both Spirogen Ltd. and ADC Therapeutics. The company also announced that Mr. Forer becomes vice chairman of the company, and will continue to work with the company as executive vice president focused on its public markets capital strategy, business and finance activities.

Similar Private Companies By Industry

Company Name Region
Arena Pharmaceuticals GmbH Europe
Abbott Service AG Europe
Joint Development Vehicle Europe
Laboratoire Sanoflore SA Europe
Sigma-Aldrich Production GmbH Europe

Recent Private Companies Transactions

Private Placement
September 2, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ADC Therapeutics SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at